DIVIS LABORATORIES
Back to Income Statement
|
DIVIS LABORATORIES Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹9,360 Cr | ₹7,845 Cr | ₹7,767 Cr | ₹895,983 Cr | ₹6,969 Cr |
What is the latest Revenue of DIVIS LABORATORIES ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹9,360 Cr |
| Mar2025 | ₹7,845 Cr |
| Mar2024 | ₹7,767 Cr |
| Mar2023 | ₹895,983 Cr |
| Mar2022 | ₹6,969 Cr |
How is Revenue of DIVIS LABORATORIES Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹9,360 Cr | 19.31 | |
| Mar2025 | ₹7,845 Cr | 1.00 | |
| Mar2024 | ₹7,767 Cr | -99.13 | |
| Mar2023 | ₹895,983 Cr | 12,755.96 | |
| Mar2022 | ₹6,969 Cr | - | |
Compare Revenue of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹225,675.0 Cr | 0.7% | 17.1% | 40.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹458,249.0 Cr | 1% | -2.7% | 15.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,891.0 Cr | -0.3% | -3.7% | 37.9% | Stock Analytics | |
| CIPLA | ₹115,927.0 Cr | -0.3% | 2.3% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,702.0 Cr | -1.4% | 0.7% | -6.2% | Stock Analytics | |
| MANKIND PHARMA | ₹98,086.5 Cr | -1.2% | -7.2% | -3.5% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 0.7% |
17.1% |
40.1% |
| SENSEX | -0.5% |
1.3% |
-4% |
You may also like the below Video Courses